Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julie Francis

Pediatric Dermatology Bellevue, WA Medical Doctor

NPI 1023112174 CMS profile 318313

14030 Ne 24Th St, Suite 202, Bellevue, WA 98007

Open in the dashboard

General payments

$5,708

252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julie Francis of Bellevue, WA is reported in the CMS Open Payments database as having received $5,708 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Pediatric Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60 1
2024 General $999 41
2023 General $2,892 145
2022 General $985 41
2021 General $57 3
2020 General $138 2
2019 General $577 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Francis
  • Pediatric Dermatology median
  • Middle half of Pediatric Dermatology
  • National median

In program year 2025, general payments to Julie Francis were reported at $60. Among 172 Pediatric Dermatology profiles paid that year, the median was $302 and the middle half received between $110 and $2,128.

Show as a table
Year Julie Francis Pediatric Dermatology median Middle half National median
2019 $577 $280 $89–$1,853 $163
2020 $138 $263 $71–$2,376 $114
2021 $57 $227 $69–$1,800 $132
2022 $985 $289 $69–$1,516 $149
2023 $2,892 $537 $114–$3,255 $160
2024 $999 $437 $114–$2,693 $164
2025 $60 $302 $110–$2,128 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $930 43 payments
  2. Pfizer Inc. $695 40 payments
  3. Janssen Biotech, Inc. $515 22 payments
  4. Incyte Corporation $436 15 payments
  5. Novartis Pharmaceuticals Corporation $395 27 payments
  6. Galderma Laboratories, L.P. $387 18 payments
  7. Regeneron Healthcare Solutions, Inc. $374 13 payments
  8. Genzyme Corporation $319 12 payments
  9. UCB, Inc. $243 6 payments
  10. LEO Pharma Inc. $237 11 payments
  11. Other $1,177 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,605 250 payments
  2. Education $100 1 payment
  3. Grant $3 1 payment
Products named General payments · program years 2019–2025
  1. CIBINQO $630 38 payments
  2. TREMFYA $515 22 payments
  3. DUPIXENT Immunology $513 20 payments
  4. EUCRISA $474 32 payments
  5. SKYRIZI $456 17 payments
  6. RINVOQ $447 25 payments
  7. OPZELURA $436 15 payments
  8. DUPIXENT Inflammation And Immunology $347 11 payments
  9. COSENTYX $308 26 payments
  10. LITFULO $262 16 payments
  11. Other $2,402 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$8,946

Medicare's payments for the services billed

Medicare patients

44

Average age 72

Services billed

226

28 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 39%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $108
  • Regeneron Healthcare Solutions, Inc. $77
$184 — —
Bimzelx
  • UCB, Inc. $88
$88 — —
TREMFYA
  • Janssen Biotech, Inc. $68
$68 — —
SKYRIZI
  • AbbVie, Inc. $67
$67 — —
ADBRY
  • LEO Pharma Inc. $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Dermatology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record